242 related articles for article (PubMed ID: 21104730)
21. Direct stenting in the DES era: Can we do better?
Bass TA
Catheter Cardiovasc Interv; 2007 Oct; 70(4):513-4. PubMed ID: 17896409
[No Abstract] [Full Text] [Related]
22. High glycemic stenting menu.
Hillegass WB
Catheter Cardiovasc Interv; 2010 Dec; 76(7):934-5. PubMed ID: 21108370
[No Abstract] [Full Text] [Related]
23. Coronary stent fracture: the hidden truth of a problem more common than stent thrombosis.
Carroll JD
Catheter Cardiovasc Interv; 2009 Jan; 73(1):88-9. PubMed ID: 19089948
[No Abstract] [Full Text] [Related]
24. Real world safety and efficacy of the Janus Tacrolimus-Eluting stent: long-term clinical outcome and angiographic findings from the Tacrolimus-Eluting STent (TEST) registry.
Tamburino C; Di Salvo ME; Capodanno D; Capranzano P; Parisi R; Mirabella F; Scardaci F; Ussia G; Galassi AR; Fiscella D; Mehran R; Dangas G
Catheter Cardiovasc Interv; 2009 Feb; 73(2):243-8. PubMed ID: 19156896
[TBL] [Abstract][Full Text] [Related]
25. Warning: this report does not address heavily calcified coronary arteries.
Butman SM
Catheter Cardiovasc Interv; 2010 Nov; 76(5):643. PubMed ID: 20976745
[No Abstract] [Full Text] [Related]
26. Neovascular microchannels in sirolimus-eluting stent occlusion at late phase.
Takano M; Yamamoto M; Seino Y; Mizuno K
JACC Cardiovasc Interv; 2010 Nov; 3(11):1202-3. PubMed ID: 21087758
[No Abstract] [Full Text] [Related]
27. Better results with the new generation bare metal stents.
Vik-Mo H
Scand Cardiovasc J; 2009 Apr; 43(2):84-6. PubMed ID: 19117238
[No Abstract] [Full Text] [Related]
28. Another small step for small vessels.
Morrison DA
Catheter Cardiovasc Interv; 2010 Jul; 76(1):67-9. PubMed ID: 20578195
[No Abstract] [Full Text] [Related]
29. Clinical and angiographic outcomes in diabetics from the ENDEAVOR IV trial: randomized comparison of zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease.
Kirtane AJ; Patel R; O'Shaughnessy C; Overlie P; McLaurin B; Solomon S; Mauri L; Fitzgerald P; Popma JJ; Kandzari DE; Leon MB
JACC Cardiovasc Interv; 2009 Oct; 2(10):967-76. PubMed ID: 19850257
[TBL] [Abstract][Full Text] [Related]
30. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial.
Leon MB; Nikolsky E; Cutlip DE; Mauri L; Liberman H; Wilson H; Patterson J; Moses J; Kandzari DE;
JACC Cardiovasc Interv; 2010 Oct; 3(10):1043-50. PubMed ID: 20965463
[TBL] [Abstract][Full Text] [Related]
31. Comparison of bare metal stent with pioglitazone versus sirolimus-eluting stent for percutaneous coronary intervention in patients with Type 2 diabetes mellitus.
Nishio K; Shigemitsu M; Kodama Y; Konno N; Katagiri T; Kobayashi Y
Cardiovasc Revasc Med; 2009; 10(1):5-11. PubMed ID: 19159848
[TBL] [Abstract][Full Text] [Related]
32. Repetita iuvant.
Colombo A
Catheter Cardiovasc Interv; 2008 Oct; 72(4):468-9. PubMed ID: 18819144
[No Abstract] [Full Text] [Related]
33. Multiple stent fractures at the site of coronary artery bypass insertion.
Hetterich H; Rieber J
Catheter Cardiovasc Interv; 2009 Jan; 73(1):84-7. PubMed ID: 19089946
[TBL] [Abstract][Full Text] [Related]
34. Sirolimus- versus paclitaxel-eluting stents for unselected patients with coronary artery disease.
Park SJ
Catheter Cardiovasc Interv; 2011 Jan; 77(1):13-4. PubMed ID: 21181967
[No Abstract] [Full Text] [Related]
35. Clinical and angiographic results with the next-generation resolute stent system: a prospective, multicenter, first-in-human trial.
Meredith IT; Worthley S; Whitbourn R; Walters DL; McClean D; Horrigan M; Popma JJ; Cutlip DE; DePaoli A; Negoita M; Fitzgerald PJ;
JACC Cardiovasc Interv; 2009 Oct; 2(10):977-85. PubMed ID: 19850258
[TBL] [Abstract][Full Text] [Related]
36. The pros and cons of living on the edge.
Butman S
Catheter Cardiovasc Interv; 2007 Oct; 70(4):504. PubMed ID: 17896412
[No Abstract] [Full Text] [Related]
37. Stent fracture, an incidental finding or a significant marker of clinical in-stent restenosis?
Shaikh F; Maddikunta R; Djelmami-Hani M; Solis J; Allaqaband S; Bajwa T
Catheter Cardiovasc Interv; 2008 Apr; 71(5):614-8. PubMed ID: 18360853
[TBL] [Abstract][Full Text] [Related]
38. Optical coherence tomography to diagnose under-expansion of a drug-eluting stent.
Motreff P; Souteyrand G
JACC Cardiovasc Imaging; 2009 Feb; 2(2):245-6; author reply 246. PubMed ID: 19356563
[No Abstract] [Full Text] [Related]
39. A randomized, controlled, multicenter trial to evaluate the safety and efficacy of zotarolimus- versus paclitaxel-eluting stents in de novo occlusive lesions in coronary arteries The ZoMaxx I trial.
Chevalier B; Di Mario C; Neumann FJ; Ribichini F; Urban P; Popma JJ; Fitzgerald PJ; Cutlip DE; Williams DO; Ormiston J; Grube E; Whitbourn R; Schwartz LB;
JACC Cardiovasc Interv; 2008 Oct; 1(5):524-32. PubMed ID: 19463354
[TBL] [Abstract][Full Text] [Related]
40. Stent fracture: an unusual cause of late restenosis after sirolimus-eluting stent placement.
Mehrle A; Skelton T; Almonacid A
Catheter Cardiovasc Interv; 2007 Jun; 69(7):988-91. PubMed ID: 17191207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
